Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 3/20 | 0.43 |
| ▸ | TRPV6 | Q9H1D0 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.39 |
| ▸ | DRD2 | P14416 | 3/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | KHK | P50053 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tert-Butyl Formate SCHEMBL25192435 | 0.89 | KMT2A (0.37) | HPGDKMT2ASMN1; SMN2ABCB1HTR2C | |
| SCHEMBL17376358 | 0.83 | HTR2C (0.61) | HTR2CHTR1AHTR2A | |
| SCHEMBL15901130 | 0.82 | HTR2C (0.43) | KMT2AHTR2CDRD2HTR2A | |
| SCHEMBL25192434 | 0.76 | ABCB1 (0.40) | KMT2AABCB1TRPV6HTR1AADRA1D | |
| SCHEMBL25191447 | 0.76 | STS (0.44) | KMT2AABCB1TRPV6 | |
| SCHEMBL8105199 | 0.74 | HTR7 (0.56) | HTR2CHTR1ADRD2HTR7 | |
| SCHEMBL19288830 | 0.73 | HPGD (0.52) | HPGDKMT2ASMN1; SMN2ABCB1HTR2C | |
| SCHEMBL20180449 | 0.69 | HTR6 (0.61) | HTR2CHTR1AADRA1BDRD2HTR7 | |
| SCHEMBL23944138 | 0.68 | MEN1 (0.53) | KMT2AHTR2C | |
| SCHEMBL10036163 | 0.68 | HTR1D (0.49) | ABCB1ADRA1DADRA1AADRA1BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339936-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | CYTOSINLAB THERAPEUTICS CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| EP-4186901-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | Cytosinlab Therapeutics Co., Ltd. (CN) | 2023-05-31 | — | — | EP | disclosed |
| WO-2022017434-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | 上海赛岚生物科技有限公司 | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339936-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | FLT3, ERBB2, ABL1 | HPGD 4284/4885KMT2A 887/4885SMN1; SMN2 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.